EM
MCID: ERY003
MIFTS: 56

Erythema Multiforme (EM)

Categories: Immune diseases, Oral diseases, Rare diseases, Skin diseases

Aliases & Classifications for Erythema Multiforme

MalaCards integrated aliases for Erythema Multiforme:

Name: Erythema Multiforme 12 73 20 36 54 44 15 17 70 32
Erythema Polymorphe, Erythema Multiforme Type 20
Dermatostomatitis, Erythema Multiforme Type 20
Herpes Iris, Erythema Multiforme Type 20
Febrile Mucocutaneous Syndrome 20
Erythema Multiforme Bullosum 20
Stevens-Johnson Syndrome 70
Em 20

Classifications:



External Ids:

Disease Ontology 12 DOID:0050185
KEGG 36 H01695
MeSH 44 D004892
ICD10 32 L51 L51.9
UMLS 70 C0014742 C0038325

Summaries for Erythema Multiforme

KEGG : 36 Erythema multiforme (EM) is an immune-mediated, mucocutaneous condition characterized by "target" lesions. Classically, EM has been separated into 2 subgroups, EM minor and EM major. In EM minor, lesions often present as papules, which might enlarge and eventually form the typical target lesion with erythema surrounding an area of central clearing. The rash in EM minor preferentially affects the limbs, specifically the extensor surfaces, however, it can also be seen throughout the body, excluding mucous membranes. EM major has mucous membrane involvement. The oral mucosa is most commonly affected, initially with edema that progresses to superficial erosions. Other surfaces that might be involved include the anogenital, ocular, and nasal mucosa. Although previously thought to be on a similar continuum of EM, and histologically appearing the same, Stevens-Johnson syndrome (SJS) is increasingly being considered a separate disease process. It is currently believed that EM is a result of an immune reaction to an inciting infectious or pharmacologic antigen. The most common infectious organisms in EM are herpes simplex virus types 1 and 2, as well as Mycoplasma pneumonia. The first line of treatment for EM is removal of the inciting factor when possible. Systemic steroids have been suggested as adjuvant therapy based on their immunosuppressant effects. To date, their use has been limited to EM major, as EM minor is self-limited.

MalaCards based summary : Erythema Multiforme, also known as erythema polymorphe, erythema multiforme type, is related to severe cutaneous adverse reaction and fixed drug eruption. An important gene associated with Erythema Multiforme is DSP (Desmoplakin), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Clotrimazole and Miconazole have been mentioned in the context of this disorder. Affiliated tissues include skin, eye and t cells, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Disease Ontology : 12 A skin disease that is a type of allergic reaction located in skin, which occurs in response to medications, infections, or illness.

GARD : 20 Erythema multiforme (EM) refers to a group of hypersensitivity disorders characterized by symmetric red, patchy lesions, primarily on the arms and legs. The cause is unknown, but EM frequently occurs in association with herpes simplex virus, suggesting an immunologic process initiated by the virus. In half of the cases, the triggering agents appear to be medications, including anticonvulsants, sulfonamides, nonsteroidal anti-inflammatory drugs, and other antibiotics. In addition, some cases appear to be associated with infectious organisms such as Mycoplasma pneumoniae and many viral agents. Erythema multiforme is the mildest of three skin disorders that are often discussed in relation to each other. It is generally the mildest of the three. More severe is Stevens-Johnson syndrome. The most severe of the three is toxic epidermal necrolysis (TEN).

Wikipedia : 73 Erythema multiforme (EM) is a skin condition of unknown cause; it is a type of erythema possibly... more...

Related Diseases for Erythema Multiforme

Diseases related to Erythema Multiforme via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 752)
# Related Disease Score Top Affiliating Genes
1 severe cutaneous adverse reaction 32.1 TNF GZMB GNLY FASLG
2 fixed drug eruption 30.8 IL2 IFNG
3 pemphigoid 30.8 TNF IL5 IL4 IFNG
4 syphilis 30.7 TNF IL6 IFNG
5 pemphigus 30.7 TNF IL6 IL4 DSP
6 herpes zoster 30.6 TNF IL2 IFNG
7 chronic graft versus host disease 30.6 IFNG CCL5
8 kawasaki disease 30.4 TNF IL6 IL4
9 exanthem 30.4 TNF IL6 IL2 IFNG CXCL8
10 diphtheria 30.3 TNF IL5 IL4 IL2
11 dermatitis herpetiformis 30.2 TNF IL5 IL4 CXCL8
12 chickenpox 30.2 TNF IL6 IL4 IL2 IFNG
13 human cytomegalovirus infection 30.2 IL6 CXCL8 CCL5
14 measles 30.2 TNF IL6 IL2 IFNG
15 erythema nodosum 30.1 TNF IL6 IFNG ICAM1 CXCL8
16 cryoglobulinemia 30.1 TNF IL6 IFNG
17 alopecia 30.1 TNF IL4 IL2 IFNG DSP
18 purpura 30.1 TNF IL6 IL4 IFNG
19 spondylitis 30.1 TNF IL6 IFNG
20 tuberculoid leprosy 30.1 TNF IL2 IFNG
21 acute generalized exanthematous pustulosis 30.1 PTGS2 CXCL8
22 superficial basal cell carcinoma 30.1 TNF IL6 IL2
23 cellulitis 30.1 TNF IL6 IL5
24 sarcoidosis 1 30.1 TNF IL2 IFNG ICAM1 CCL5
25 cutaneous lupus erythematosus 29.9 TNF IL6 IFNG ICAM1 CCL17
26 poliomyelitis 29.9 TNF IL4 IFNG ICAM1
27 graft-versus-host disease 29.9 TNF IL6 IL2 IFNG GZMB FASLG
28 haemophilus influenzae 29.9 TNF CXCL8
29 systemic scleroderma 29.9 TNF IL6 IL4 IFNG
30 bacterial infectious disease 29.9 TNF IL6 IFNG CXCL8
31 mature t-cell and nk-cell lymphoma 29.9 TIA1 IL2 GZMB
32 neutropenia 29.8 TNF IL6 IL2 FASLG CXCL8
33 urticaria 29.8 TNF PTGS2 IL6 IL5 IL4 CXCL8
34 pertussis 29.8 TNF IL6 CXCL8 CCL5
35 pharyngitis 29.8 TNF PTGS2 IL6 CXCL8
36 covid-19 29.8 IL6 IL4 CXCL8
37 orofacial granulomatosis 29.8 TNF IL4 IFNG CCL5
38 peptic ulcer disease 29.7 TNF PTGS2 CXCL8
39 keratitis, hereditary 29.7 TNF IL6 CXCL8
40 acute graft versus host disease 29.7 TNF IL4 IL2 IFNG FASLG
41 tetanus 29.7 TNF IL6 IL5 IL4 IL2 IFNG
42 severe acute respiratory syndrome 29.7 TNF IL6 IFNG CXCL8 CCL5
43 pulpitis 29.6 TNF IL6 CXCL8
44 dysentery 29.6 TNF IL6 CXCL8
45 chlamydia pneumonia 29.6 TNF IL6 IL4 CXCL8
46 acute cystitis 29.6 TNF IL6 CXCL8
47 hepatitis b 29.6 TNF IL6 IFNG CXCL8
48 legionellosis 29.5 TNF IL6 CXCL8
49 smallpox 29.5 TNF IL4 IL2 IFNG ICAM1 GZMB
50 vaccinia 29.5 TNF IL6 IL2 ICAM1 GZMB

Comorbidity relations with Erythema Multiforme via Phenotypic Disease Network (PDN):


Acute Cystitis Deficiency Anemia
Heart Disease

Graphical network of the top 20 diseases related to Erythema Multiforme:



Diseases related to Erythema Multiforme

Symptoms & Phenotypes for Erythema Multiforme

GenomeRNAi Phenotypes related to Erythema Multiforme according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.28 CXCL8 GZMB TNF
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.28 CXCL8 GZMB ICAM1 IL2 TNF
3 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-3 9.28 ICAM1

MGI Mouse Phenotypes related to Erythema Multiforme:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.18 CCL17 CCL5 FASLG ICAM1 IFNG IL2
2 immune system MP:0005387 10.18 CCL17 CCL5 DSP FASLG ICAM1 IFNG
3 cellular MP:0005384 10.16 CCL17 DSP FASLG ICAM1 IFNG IL2
4 digestive/alimentary MP:0005381 10.13 DSP FASLG ICAM1 IFNG IL2 IL4
5 integument MP:0010771 9.92 DSP FASLG ICAM1 IFNG IL4 IL6
6 liver/biliary system MP:0005370 9.86 FASLG IFNG IL2 IL4 IL5 IL6
7 neoplasm MP:0002006 9.76 FASLG ICAM1 IFNG IL2 IL5 IL6
8 respiratory system MP:0005388 9.56 FASLG IFNG IL2 IL4 IL5 IL6
9 vision/eye MP:0005391 9.28 DSP FASLG ICAM1 IFNG IL2 IL4

Drugs & Therapeutics for Erythema Multiforme

Drugs for Erythema Multiforme (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 59)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
2
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
3
Clobetasol Approved, Experimental, Investigational Phase 4 25122-41-2, 25122-46-7 32798 5311051
4
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
5
Molgramostim Investigational Phase 4 99283-10-0
6 Immunosuppressive Agents Phase 4
7 Anti-Inflammatory Agents Phase 4
8 Dermatologic Agents Phase 4
9 Calcineurin Inhibitors Phase 4
10 Anti-Infective Agents Phase 4
11 Antifungal Agents Phase 4
12 Ophthalmic Solutions Phase 4
13 glucocorticoids Phase 4
14 Hormone Antagonists Phase 4
15 Hormones Phase 4
16 Respiratory System Agents Phase 4
17 Anti-Asthmatic Agents Phase 4
18 Betamethasone benzoate Phase 4
19 Betamethasone-17,21-dipropionate Phase 4
20 Betamethasone Valerate Phase 4 2152-44-5
21 Betamethasone sodium phosphate Phase 4
22 Calcipotriene Phase 4
23
Coal tar Approved Phase 3 8007-45-2
24
Etanercept Approved, Investigational Phase 3 185243-69-0
25
Sargramostim Approved, Investigational Phase 2, Phase 3 123774-72-1, 83869-56-1
26
Lenograstim Approved, Investigational Phase 2, Phase 3 135968-09-1
27 Analgesics, Non-Narcotic Phase 3
28 Immunologic Factors Phase 2, Phase 3
29 Analgesics Phase 3
30 Anti-Inflammatory Agents, Non-Steroidal Phase 3
31 Pharmaceutical Solutions Phase 2, Phase 3
32 Adjuvants, Immunologic Phase 2, Phase 3
33
Pembrolizumab Approved Phase 2 1374853-91-4
34
Folic acid Approved, Nutraceutical, Vet_approved Phase 1, Phase 2 59-30-3 6037
35
Riboflavin Approved, Investigational, Nutraceutical, Vet_approved Phase 1, Phase 2 83-88-5 493570
36 Vitamin B9 Phase 1, Phase 2
37 Nutrients Phase 1, Phase 2
38 Micronutrients Phase 1, Phase 2
39 Trace Elements Phase 1, Phase 2
40 Photosensitizing Agents Phase 1, Phase 2
41 Vitamins Phase 1, Phase 2
42 Vitamin B Complex Phase 1, Phase 2
43 Vitamin B2 Phase 1, Phase 2
44 Folate Phase 1, Phase 2
45 Antineoplastic Agents, Immunological Phase 2
46
tannic acid Approved Phase 1 1401-55-4
47
Benzocaine Approved, Investigational Phase 1 1994-09-7, 94-09-7 2337
48 Anesthetics Phase 1
49 Anesthetics, Local Phase 1
50
Allopurinol Approved 315-30-0 2094

Interventional clinical trials:

(show all 33)
# Name Status NCT ID Phase Drugs
1 Efficacy of 0.05% Cyclosporin Eye Drop in Stevens Johnson Syndrome Patient With Chronic Dry Eye Completed NCT01488396 Phase 4 0.05%cyclosporin eye drop
2 The Effect of Enstilar Versus Vehicle on Target Lesions in Moderate Plaque Type Psoriasis Patients Completed NCT03848871 Phase 4 Enstilar
3 Subject Reported Target-lesion Numeric Rating Scale Evaluation by Subjects With Plaque Psoriasis Treated With Clobex® (Clobetasol Propionate) Spray 0.05% Completed NCT01893567 Phase 4 Clobex Spray
4 Evaluation of G-CSF as a Treatment of Toxic Epidermal Necrolysis Recruiting NCT02739295 Phase 4 recombinant granulocyte - colony stimulating factor;NaCl 0.9%
5 NPB-01(Intravenous Immunoglobulin) Therapy for Patients With Stevens-Johnson Syndrome/ Toxic Epidermal Necrolysis Unresponsive to Corticosteroids. Completed NCT01696500 Phase 3 Intravenous immunoglobulin
6 Autologous ex Vivo Conjunctival Epithelial Cell Expansion for Ocular Surface Completed NCT00346450 Phase 3
7 NATIENS: A Phase III Randomized Double-Blinded Placebo Controlled Study to Determine the Optimal Management and Mechanisms of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Not yet recruiting NCT02987257 Phase 3 Harmonized supportive care;Cyclosporine 5 mg/kg bid days 0-14;Etanercept 50 mg sc day 0 and day 3
8 Evaluating the Therapeutic Efficacy of Filgrastim in Severe Bullous Drug Eruptions (Lyell and Stevens-Johnson Syndromes) Not yet recruiting NCT04651439 Phase 2, Phase 3 Filgrastim;Placebo
9 The Use of Riboflavin/Ultraviolet A Cross-linked Human Donor Corneas as Carriers for the Boston Keratoprosthesis Completed NCT01582880 Phase 1, Phase 2 Riboflavin
10 A Phase II Trial of Pembrolizumab Sequentially Following Single Fraction Non-ablative Radiation to One of the Target Lesions, in Previously Treated Patients With Stage IV NSCLC Active, not recruiting NCT02658097 Phase 2 Pembrolizumab
11 Mesenchymal Stromal Cells Treatment in Lyell Syndrome: A Pilot Phase 1-2 Open Trial Not yet recruiting NCT04711200 Phase 1, Phase 2 Adipose derived stromal cells intravenously injected
12 Palifermin Treatment of Toxic Epidermal Necrolysis Terminated NCT02037347 Phase 1, Phase 2 Palifermin
13 Infliximab Therapy to Improve Retention of the Boston Keratoprosthesis in Patients After Stevens Johnson Syndrome/ Toxic Epidermal Necrolysis Withdrawn NCT01256489 Phase 1, Phase 2 Infliximab
14 Topical Infliximab in Autoimmune Eyes With Keratoprosthesis Withdrawn NCT02126020 Phase 1, Phase 2 topical infliximab
15 Pilot Study Comparing Remicade (Infliximab) vs. Standard Care in the Treatment of Toxic Epidermal Necrolysis Withdrawn NCT00372723 Phase 2 Remicaide (infliximab)
16 A Randomized Placebo Controlled Split-body Double-blind Phase II Clinical Trial to Investigate the Safety and Efficacy of Clobetasol 0.05% Ointment for the Treatment of Toxic Epidermal Necrolysis (TEN) Withdrawn NCT02319616 Phase 1, Phase 2 Clobetasol 0.05% ointment;Placebo
17 Platelet Rich-plasma in Management of Chronic Multiple Oral Ulcers Completed NCT03878771 Phase 1 Dermovate cream in Orabase
18 Comparison of Corneal Epitheliotropic Factors in Autologous Serum Eye Drops Between Nonautoimmune Dry Eye and Stevens-Johnson Syndrome With Dry Eye Unknown status NCT01122303
19 A Prospective Study to Prove the Usefulness of HLA-B*5801 Screening Test for the Prevention of Allopurinol-induced Severe Cutaneous Adverse Reaction in Patient With Chronic Kidney Disease Unknown status NCT03046914
20 The Multicenter Registry of Patients With Severe Cutaneous Adverse Reactions Among Tertiary Medical Institutes in Thailand Unknown status NCT02574988
21 Evaluating the Effect of Isotretinoin in Regulatory T-cell Function in Adverse Cutaneous Drug Eruptions (ACDEs): A Pilot Study Unknown status NCT02795143 Isotretinoin
22 Salivary Gland and Labial Mucous Membrane Transplantation in the Treatment of Severe Symblepharon and Dry Eye in Patients With Stevens-Johnson Syndrome. Completed NCT01178242
23 Stevens-Johnson Syndrome Associated With Antimicrobial Completed NCT00844038
24 A Prospective Open-label, Multicenter Clinical Investigation to Assess the Safety and Performance of ARGOS-IO System in Patients Undergoing Implantation of a Boston Keratoprosthesis (BKPro) Completed NCT02945176
25 Prostate Biopsies With Target Lesion on MRI : When Can Non-targeted Biopsies be Dispensed With Completed NCT04692207
26 Relation Among Cholesterol Uptake Capacity Which Measure HDL Functionality, Neoatherosclerosis and Target Lesion Revascularization After Stent Implantation Completed NCT03540381
27 Assessing the Detection of Clinically Significant Prostate Cancer Using Magnetic Resonance Imaging-Guided Transperineal Targeted Biopsy Compared to Standard Transrectal Biopsy Outcomes Study: The ASTROS Trial Completed NCT03044197
28 Adverse Cutaneous Drug Reactions Collection of Clinical Data and Biological Samples Recruiting NCT03659227
29 An Evaluation of Tangible Boost Replenishing System for Patients With Stevens Johnson Syndrome, Sjogren's Syndrome, and Graft Versus Host Disease Recruiting NCT04313725
30 The Effects of Minor Salivary Gland Transplantation for Cicatrizing Conjunctivitis Recruiting NCT03839069
31 Association of Cytokines With the Development of Complications in Burn and Toxic Epidermal Necrolysis (TENS) Patients Recruiting NCT04252651
32 An Investigator-initiated Trial (IIT) on the Effect of Autologous Oral Mucosal Epithelial Sheet Transplantation in Corneal Limbal Deficiency Patients Available NCT02149732
33 A Prospective Multicenter Cohort Study Assessing Outcomes in Stevens Johnsons Syndrome and Toxic Epidermal Necrolysis Not yet recruiting NCT03585946 Site specific standard of care comparison

Search NIH Clinical Center for Erythema Multiforme

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Thalidomide

Cochrane evidence based reviews: erythema multiforme

Genetic Tests for Erythema Multiforme

Anatomical Context for Erythema Multiforme

The Foundational Model of Anatomy Ontology organs/tissues related to Erythema Multiforme:

19
Skin

MalaCards organs/tissues related to Erythema Multiforme:

40
Skin, Eye, T Cells, Salivary Gland, Prostate, Breast, Endothelial

Publications for Erythema Multiforme

Articles related to Erythema Multiforme:

(show top 50) (show all 5789)
# Title Authors PMID Year
1
Detection of autoantibodies to desmoplakin in a patient with oral erythema multiforme. 54 61
17478387 2007
2
Serious skin reactions and selective COX-2 inhibitors: a case series from prescription-event monitoring in England. 61 54
16872242 2006
3
Internalization via plasmalemmal vesicles: a route for antidesmoplakin autoantibodies into cultured human keratinocytes. 61 54
14705794 2003
4
[Erythema multiforme. A heterogeneous pathologic phenotype]. 54 61
10434539 1999
5
Erythema multiforme associated human autoantibodies against desmoplakin I and II. 61 54
10084323 1999
6
Antibodies to desmoplakin in a patient with pemphigus foliaceous. 61 54
9784047 1998
7
Erythema multiforme associated human autoantibodies against desmoplakin I and II: biochemical characterization and passive transfer studies into newborn mice. 61 54
9740248 1998
8
Autoantibodies against desmoplakin I and II define a subset of patients with erythema multiforme major. 54 61
8618031 1996
9
Erythema-multiforme-like eruption due to topical contactants: expression of adhesion molecules and their ligands and characterization of the infiltrate. 61 54
8565488 1995
10
In three types of interface dermatitis, different patterns of expression of intercellular adhesion molecule-1 (ICAM-1) indicate different triggers of disease. 61 54
7616001 1995
11
Autoantibodies to desmoplakin I and II in patients with erythema multiforme. 61 54
7807001 1995
12
Cytokine modulation of adhesion molecules in the regulation of immunologic cytotoxicity of epidermal targets. 54 61
2258627 1990
13
A beginner's guide to mucous membrane grafting for lid margin keratinization: Review of indications, surgical technique and clinical outcomes. 61
33727438 2021
14
Cohort study on adverse drug reactions in adults admitted to the medical wards of a tertiary hospital in Nigeria: Prevalence, incidence, risk factors and fatality. 61
32991765 2021
15
Mortality and risk factors on admission in toxic epidermal necrolysis: A cohort study of 59 patients. 61
33279401 2021
16
Skin manifestations of COVID-19 in children: Part 3. 61
33207021 2021
17
Skin manifestations of COVID-19 in children: Part 2. 61
33166429 2021
18
Skin manifestations of COVID-19 in children: Part 1. 61
33180982 2021
19
Time of Onset of Selected Skin Lesions Associated with COVID-19: A Systematic Review. 61
33811315 2021
20
Lacrimal Gland Involvement in Severe Dry Eyes after Stevens-Johnson Syndrome. 61
32835747 2021
21
Immunohistochemical Expression of PD-L1 Is Increased in Lesional Epidermal Keratinocytes in Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis. 61
33055536 2021
22
Mucous membrane grafting for lid margin keratinization in Stevens Johnson syndrome - An eye opening saga. 61
33727433 2021
23
SkinSerious: Disseminated intravascular coagulation complicating Stevens-Johnson syndrome and toxic epidermal necrolysis. 61
33515629 2021
24
Potentially life‑threatening severe cutaneous adverse reactions associated with tyrosine kinase inhibitors (Review). 61
33650659 2021
25
Levamisole induced toxic epidermal necrolysis: A case report. 61
32851655 2021
26
Amniotic membrane transplantation in a 2-month-old infant with toxic epidermal necrolysis. 61
33521381 2021
27
Toxic Epidermal Necrolysis Like Lupus - A Case Series. 61
33760256 2021
28
MEEI special issue Fellows' PaperStevens Johnson syndrome: A review of a vision and life-threatening mucocutaneous disease including histopathology with updates on pathogenesis and genetic risk factors. 61
33764253 2021
29
The risk of anti-osteoporotic agent-induced severe cutaneous adverse drug reactions and their association with HLA. 61
32896010 2021
30
Interdisciplinary Safety Evaluation for Learning and Decision-Making. 61
33730364 2021
31
Blistering severe cutaneous adverse reactions in children: Proposal for pediatric-focused clinical criteria. 61
33730370 2021
32
Characteristics of adverse drug reactions associated with antiepileptics at a tertiary children's hospital in Japan: A retrospective observational cohort study. 61
33740697 2021
33
Rash and Mucositis Associated With Mycoplasma pneumoniae and Chlamydophila pneumoniae: A Recurrence of MIRM? 61
32275058 2021
34
In Silico Approach to Predict Severe Cutaneous Adverse Reactions Using the Japanese Adverse Drug Event Report Database. 61
33417306 2021
35
Systematic review of BRAF/MEK inhibitors-induced Severe Cutaneous Adverse Reactions (SCARs). 61
32846030 2021
36
ERYTHEMA MULTIFORME-LIKE LESIONS IN A CHILD. 61
33635580 2021
37
Bee propolis-induced erythema multiforme. 61
33757675 2021
38
Erythema multiforme minor during sublingual immunotherapy. 61
33650188 2021
39
Itraconazole-induced photodistributed erythema multiforme. 61
33605022 2021
40
Prompt onset of erythema multiforme following the first BNT162b2 SARS-CoV-2 vaccination. 61
33725406 2021
41
Management of Stevens-Johnson syndrome using a mini-scleral contact lens. 61
33107055 2021
42
Supportive care in the acute phase of Stevens-Johnson syndrome and toxic epidermal necrolysis: an international, multidisciplinary DELPHI-based consensus. 61
33657677 2021
43
Evaluation of drug patch tests in children. 61
33685563 2021
44
Cohort study of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis in China: evaluation of risk models and new predictor of pulmonary consolidation on computed tomography. 61
33644844 2021
45
Long-term sequelae from Stevens-Johnson syndrome/toxic epidermal necrolysis in a large retrospective cohort. 61
32289398 2021
46
Patients', family members' and healthcare practitioners' experiences of Stevens-Johnson syndrome and toxic epidermal necrolysis: a qualitative descriptive study using emotional touchpoints. 61
32977354 2021
47
Acute pancreatic injuries: A complication of Stevens-Johnson syndrome/toxic epidermal necrolysis associated with cytotoxic immunocell activation. 61
32561372 2021
48
Severe Cutaneous Adverse Reactions to Anti-tuberculosis Drugs in Korean Patients. 61
33474859 2021
49
Involvement of small-diameter nerve fibres in long-term chronic pain after Stevens-Johnson syndrome or toxic epidermal necrolysis. A neurophysiological assessment. 61
32920914 2021
50
[Ocular involvement in Stevens-Johnson syndrome and toxic epidermal necrolysis]. 61
33725172 2021

Variations for Erythema Multiforme

Expression for Erythema Multiforme

Search GEO for disease gene expression data for Erythema Multiforme.

Pathways for Erythema Multiforme

Pathways related to Erythema Multiforme according to GeneCards Suite gene sharing:

(show top 50) (show all 79)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.08 TNF PTGS2 IL6 IL5 IL4 IL2
2
Show member pathways
13.89 TNF PTGS2 IL6 IL5 IL4 IL2
3
Show member pathways
13.74 TNF PTGS2 IL6 IL5 IL4 IL2
4
Show member pathways
13.62 TNF IL6 IL5 IL4 IL2 IFNG
5
Show member pathways
13.5 TNF IL6 IL5 IL4 IL2 FASLG
6
Show member pathways
13.41 TNF PTGS2 IL6 IL5 IL4 IL2
7
Show member pathways
13.39 TNF IL6 IL5 IL4 IL2 FASLG
8
Show member pathways
13.3 TNF IL6 IL2 IFNG ICAM1 FASLG
9
Show member pathways
13.05 TNF PTGS2 IL6 IL4 IL2 FASLG
10
Show member pathways
13.05 TNF PTGS2 IL6 ICAM1 FASLG CXCL8
11 12.96 PTGS2 IL6 IL5 IL4 IL2 IFNG
12
Show member pathways
12.93 TNF IL6 IL2 IFNG ICAM1 FASLG
13 12.85 TNF IL6 IFNG FASLG CCL5
14
Show member pathways
12.72 TNF IL6 IL5 IL4 IL2 IFNG
15
Show member pathways
12.71 TNF IL6 IL5 IL4 IL2 IFNG
16
Show member pathways
12.64 TNF IL4 IL2 IFNG ICAM1 GZMB
17 12.64 TNF PTGS2 IL4 IL2 IFNG GZMB
18
Show member pathways
12.51 IL6 IL5 IL4 IL2 IFNG
19
Show member pathways
12.47 TNF IL6 IL2 CXCL8 CCL5 CCL17
20
Show member pathways
12.44 TNF IL6 IL5 IL4 IL2 IFNG
21
Show member pathways
12.42 TNF PTGS2 IL6 IFNG CXCL8
22
Show member pathways
12.41 TNF PTGS2 IL6 IL5 IL4 IFNG
23
Show member pathways
12.4 TNF IL6 IL5 IL4 IL2 IFNG
24 12.39 TNF IL6 IL2 ICAM1
25
Show member pathways
12.39 TNF PTGS2 IL6 IL4 IL2 IFNG
26
Show member pathways
12.34 TNF PTGS2 IL6 IL2 CCL17
27
Show member pathways
12.34 TNF IL6 IL4 IFNG FASLG CXCL8
28
Show member pathways
12.32 TNF PTGS2 IL4 IFNG
29 12.31 TNF TIA1 GZMB FASLG
30 12.3 TNF IL6 CXCL8 CCL5
31 12.25 TNF PTGS2 IL6 IFNG
32 12.17 TNF IL6 IL2 CXCL8
33
Show member pathways
12.13 IL4 IL2 IFNG GZMB FASLG
34 12.13 TNF IL6 IL5 IL4 IL2 IFNG
35 12.12 TNF PTGS2 IL6 ICAM1 CCL5
36 12.1 TNF PTGS2 IL6 IL4 ICAM1 FASLG
37 12.05 TNF PTGS2 ICAM1 CXCL8
38 12.03 TNF IL6 IFNG CXCL8
39 12.02 TNF IL6 ICAM1 CXCL8
40 12.02 TNF IL6 IL5 IL4
41 12.01 TNF IL6 IFNG ICAM1 CXCL8 CCL5
42
Show member pathways
11.98 IL6 IL4 IFNG GZMB
43 11.96 IL6 IFNG CXCL8
44 11.94 TNF PTGS2 IL6 IL4 IL2 IFNG
45
Show member pathways
11.9 IL6 ICAM1 CXCL8
46
Show member pathways
11.9 TNF IL6 IL2 IFNG
47 11.89 TNF IL5 IL4 IL2 IFNG GZMB
48 11.89 IL6 IL5 IL4 IL2 IFNG ICAM1
49 11.88 TNF IL6 IL2 IFNG
50 11.86 TNF IL6 IL5 IL4 ICAM1

GO Terms for Erythema Multiforme

Cellular components related to Erythema Multiforme according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.73 TNF IL6 IL5 IL4 IL2 IFNG
2 extracellular space GO:0005615 9.4 TNF IL6 IL5 IL4 IL2 IFNG

Biological processes related to Erythema Multiforme according to GeneCards Suite gene sharing:

(show top 50) (show all 55)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 10.06 TNF IL6 IL4 IFNG CXCL8
2 MAPK cascade GO:0000165 10 TNF IL5 IL2 CCL5
3 cell-cell signaling GO:0007267 9.97 IL2 FASLG CCL5 CCL17
4 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.96 TNF ICAM1 CCL5 CCL17
5 positive regulation of cell proliferation GO:0008284 9.95 PTGS2 IL6 IL5 IL4 IL2 IFNG
6 cellular response to lipopolysaccharide GO:0071222 9.92 TNF IL6 ICAM1 CXCL8
7 positive regulation of inflammatory response GO:0050729 9.89 TNF IL2 IFNG
8 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.88 IL6 IL5 ICAM1
9 positive regulation of interleukin-6 production GO:0032755 9.88 TNF IL6 IFNG
10 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.88 TNF PTGS2 IL6
11 cellular response to tumor necrosis factor GO:0071356 9.88 ICAM1 CXCL8 CCL5 CCL17
12 neutrophil chemotaxis GO:0030593 9.86 CXCL8 CCL5 CCL17
13 chemokine-mediated signaling pathway GO:0070098 9.85 CXCL8 CCL5 CCL17
14 response to glucocorticoid GO:0051384 9.84 TNF PTGS2 IL6
15 cellular response to interferon-gamma GO:0071346 9.84 ICAM1 FASLG CCL5 CCL17
16 humoral immune response GO:0006959 9.82 TNF IL6 IFNG
17 positive regulation of interleukin-1 beta production GO:0032731 9.82 TNF IL6 IFNG
18 cellular response to interleukin-1 GO:0071347 9.81 ICAM1 CXCL8 CCL5 CCL17
19 regulation of insulin secretion GO:0050796 9.8 TNF IL6 IFNG CCL5
20 inflammatory response GO:0006954 9.8 TNF PTGS2 IL6 IL5 CXCL8 CCL5
21 extrinsic apoptotic signaling pathway GO:0097191 9.79 TNF IFNG FASLG
22 monocyte chemotaxis GO:0002548 9.79 IL6 CCL5 CCL17
23 positive regulation of B cell proliferation GO:0030890 9.78 IL5 IL4 IL2
24 positive regulation of chemokine production GO:0032722 9.77 TNF IL6 IFNG
25 positive regulation of T cell proliferation GO:0042102 9.76 IL6 IL4 IL2 CCL5
26 microglial cell activation GO:0001774 9.74 TNF IL4 IFNG
27 positive regulation of smooth muscle cell proliferation GO:0048661 9.73 TNF PTGS2 IL6 CCL5
28 negative regulation of calcium ion transport GO:0051926 9.72 PTGS2 ICAM1
29 negative regulation of G protein-coupled receptor signaling pathway GO:0045744 9.72 CXCL8 CCL5
30 neutrophil activation GO:0042119 9.71 CXCL8 CCL5
31 positive regulation of neuroinflammatory response GO:0150078 9.71 TNF IL6
32 negative regulation of amyloid-beta clearance GO:1900222 9.7 TNF IFNG
33 regulation of neuroinflammatory response GO:0150077 9.7 PTGS2 IL6
34 positive regulation of immunoglobulin production GO:0002639 9.7 IL6 IL5 IL2
35 positive regulation of podosome assembly GO:0071803 9.69 TNF IL5
36 positive regulation of MHC class II biosynthetic process GO:0045348 9.69 IL4 IFNG
37 negative regulation of T-helper 17 cell differentiation GO:2000320 9.68 IL4 IL2
38 positive regulation of isotype switching to IgG isotypes GO:0048304 9.68 IL4 IL2
39 negative regulation of lipid storage GO:0010888 9.68 TNF IL6
40 necroptotic signaling pathway GO:0097527 9.67 TNF FASLG
41 positive regulation of nitric oxide biosynthetic process GO:0045429 9.67 TNF PTGS2 IFNG ICAM1
42 vascular endothelial growth factor production GO:0010573 9.66 TNF IL6
43 positive regulation of mononuclear cell migration GO:0071677 9.65 TNF IL4
44 positive regulation of leukocyte adhesion to vascular endothelial cell GO:1904996 9.65 TNF IL6 ICAM1
45 immune response GO:0006955 9.65 TNF IL6 IL5 IL4 IL2 IFNG
46 positive regulation of cellular respiration GO:1901857 9.64 IL4 IFNG
47 neuroinflammatory response GO:0150076 9.63 IL4 IFNG
48 positive regulation of fever generation GO:0031622 9.63 TNF PTGS2
49 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.63 TNF IL6 IL4 IL2 IFNG CCL5
50 positive regulation of JAK-STAT cascade GO:0046427 9.62 TNF IL6 IL5 CCL5

Molecular functions related to Erythema Multiforme according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.22 TNF TIA1 PTGS2 IL6 IL5 IL4
2 growth factor activity GO:0008083 9.46 IL6 IL5 IL4 IL2
3 chemokine activity GO:0008009 9.43 CXCL8 CCL5 CCL17
4 cytokine activity GO:0005125 9.32 TNF IL6 IL5 IL4 IL2 IFNG
5 CCR4 chemokine receptor binding GO:0031729 8.96 CCL5 CCL17

Sources for Erythema Multiforme

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....